FY2025 Earnings Forecast for Immunic Issued By William Blair

Immunic, Inc. (NASDAQ:IMUX - Free Report) - Investment analysts at William Blair raised their FY2025 earnings per share estimates for shares of Immunic in a research report issued to clients and investors on Wednesday, April 30th. William Blair analyst M. Minter now forecasts that the company will post earnings per share of ($0.86) for the year, up from their prior forecast of ($0.89). William Blair has a "Outperform" rating on the stock. The consensus estimate for Immunic's current full-year earnings is ($0.94) per share. William Blair also issued estimates for Immunic's FY2026 earnings at ($0.95) EPS, FY2027 earnings at ($0.78) EPS and FY2028 earnings at ($0.31) EPS.

Several other research analysts also recently issued reports on the stock. HC Wainwright reissued a "buy" rating and set a $10.00 price objective on shares of Immunic in a research report on Thursday, May 1st. StockNews.com cut Immunic from a "hold" rating to a "sell" rating in a research report on Thursday, March 20th. B. Riley reaffirmed a "buy" rating and set a $6.00 price objective on shares of Immunic in a research report on Wednesday, April 16th. Finally, D. Boral Capital reissued a "buy" rating and issued a $17.00 target price on shares of Immunic in a report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, six have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $13.20.

Immunic Price Performance

Shares of IMUX traded up $0.01 during mid-day trading on Monday, reaching $1.03. 396,659 shares of the company's stock were exchanged, compared to its average volume of 706,467. The business's fifty day simple moving average is $1.08 and its 200-day simple moving average is $1.10. The stock has a market capitalization of $98.21 million, a PE ratio of -0.83 and a beta of 1.73. Immunic has a 52-week low of $0.83 and a 52-week high of $2.11.

Institutional Trading of Immunic

Several hedge funds and other institutional investors have recently made changes to their positions in IMUX. Millennium Management LLC boosted its position in Immunic by 480.6% during the fourth quarter. Millennium Management LLC now owns 579,683 shares of the company's stock worth $580,000 after purchasing an additional 479,846 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Immunic by 45.6% during the 4th quarter. Renaissance Technologies LLC now owns 566,623 shares of the company's stock worth $567,000 after buying an additional 177,542 shares during the last quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Immunic by 90.0% in the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 204,579 shares of the company's stock worth $205,000 after buying an additional 96,894 shares in the last quarter. Barclays PLC acquired a new stake in Immunic in the 4th quarter valued at about $84,000. Finally, HB Wealth Management LLC purchased a new position in Immunic during the 4th quarter valued at about $81,000. Institutional investors and hedge funds own 51.82% of the company's stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.